secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2025-10-16T23:59:59+00:00
Accession:  0001171843-25-006472
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose tuspetinib combo achieves 100% CR/CRh at higher doses in newly diagnosed AML trial
--------------------------------------------------------------------------------

- TUS+VEN+AZA achieved 100% CR/CRh (6/6) at 80mg and 120mg doses, exceeding 66% expected from VEN+AZA alone.
- CR/CRh in 7/8 (88%) FLT3 wildtype AML; responses across TP53, RAS, FLT3-ITD mutations.
- No dose-limiting toxicities, QTc prolongation, differentiation syndrome, or prolonged myelosuppression seen.
- Dosing at 160mg TUS level now ongoing; trial enrolling 18-24 patients by end of 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000117184325006472/0001171843-25-006472-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000117184325006472/f8k_101525.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-006472

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer